Vivos TherapeuticsVVOS +9.34%41 Days Payable is 80.53 as of Mar. 2026, which is 20% below its 10-year median of 101.15. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.16 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Vivos Therapeutics ranks better than 58.99% on this metric.
The historical rank and industry rank for Vivos Therapeutics's Days Payable or its related term are showing as below:
VVOS'
s Days Payable Range Over the Past 10 Years
Min: 70.84 Med: 101.15 Max: 160.05
Current: 85.43
During the past 8 years, Vivos Therapeutics's highest Days Payable was 160.05. The lowest was 70.84. And the median was 101.15.
VVOS's Days Payable is ranked better than 58.99% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs VVOS: 85.43
Vivos Therapeutics's Days Payable
increased
from Mar. 2025 (69.75) to Mar. 2026 (80.53).
It may suggest that Vivos Therapeuticsdelayed paying its suppliers.
Vivos Therapeutics Days Payable Related Terms
Vivos Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vivos Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos Therapeutics (VVOS) has a Days Payable of 80.53 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vivos Therapeutics and its competitors. This is 20% below median its historical median of 101.15. Over the past decade, Vivos Therapeutics' Days Payable has ranged from 70.84 to 160.05. According to the industry distribution chart, Vivos Therapeutics ranks #326 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 41%.
Is Vivos Therapeutics' Days Payable too high?
Vivos Therapeutics' current Days Payable of 80.53 is 20% below median its 10-year median of 101.15. Over the past 10 years, this metric has ranged from a low of 70.84 to a high of 160.05. The Medical Devices & Instruments industry median Days Payable is 68.07. Vivos Therapeutics' value of 80.53 is 18.3% above this industry median. Based on the distribution chart, Vivos Therapeutics ranks #326 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Days Payable compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #326 out of 795 companies for Days Payable. This puts Vivos Therapeutics in the upper half of its industry. The industry median Days Payable is 68.07. Vivos Therapeutics' value of 80.53 is 18.3% above this benchmark. Historically, Vivos Therapeutics' own Days Payable has ranged from 70.84 to 160.05 over the past decade. While the company's 10-year median is 101.15 vs. the industry median of 68.07, Vivos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos Therapeutics's current Days Payable of 80.53 is 18.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current Days Payable is 80.53, which is 20% below median its own 10-year median of 101.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.16, compared to a current price of $0.49 — trading 57.5% below its estimated fair value. The current Days Payable is 80.53, which is 20% below median its 10-year median of 101.15 and 18.3% above the Medical Devices & Instruments industry median of 68.07. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Days Payable is 80.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.49 is trading 57.5% below its estimated GF Value™ of $1.16.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Days Payable: 80.53 (20% below median its 10-year median of 101.15)
GF Value™: $1.16 vs. price of $0.49 (57.5% below fair value)
Industry Position: 18.3% above the Medical Devices & Instruments median (#326 of 795)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score
Get the complete analysis for VVOS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
